Antimicrobial therapy of community-acquired pneumonia
- PMID: 15555836
- PMCID: PMC7118969
- DOI: 10.1016/j.idc.2004.07.011
Antimicrobial therapy of community-acquired pneumonia
Abstract
Community-acquired pneumonia (CAP) is a common disorder that is potentially life-threatening, especially in older adults and patients with comorbid disease. Despite substantial progress in therapeutic options, CAP remains a primary cause of death from infectious disease in the United States. The mainstay of treatment for most patients is appropriate antimicrobial therapy This article reviews the principles for initial antimicrobial therapy, highlights some of the differences in approaches to antimicrobial drug selection in selected guidelines, and includes new recommendations for empiric and pathogen-directed therapy of CAP.
References
-
- Fang G.D., Fine M., Orloff J. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine. 1990;69:307–316. - PubMed
-
- Marrie T.J., Peeling R.W., Fine M.J. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med. 1996;101:508–515. - PubMed
-
- Tan M.J., Tan J.S., File T.M., Jr. Legionnaire's disease with bacteremic coinfection. Clin Inf Dis. 2002;35:533–539. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous